Revolution Medicines:Daraxonrasib在针对转移性胰腺癌患者的3期Rasolute 302试验中显示总体生存获益

美股速递
Apr 13

Revolution Medicines公司宣布,其研发的Daraxonrasib在针对转移性胰腺癌患者开展的3期Rasolute 302试验中,展现出显著的总体生存获益。这一积极数据为晚期胰腺癌治疗领域带来了新的希望。

该试验结果进一步验证了Daraxonrasib在改善患者生存期方面的潜力,有望为临床治疗提供新的有效选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10